Browse by author
Lookup NU author(s): Professor Herbie Newell, Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Eighteen patients with advanced cancer have been treated intravenously with human recombinant tumour necrosis factor (rhTNF). The drug produced febrile reactions at all doses although these were preventable by steroids and indomethacin. Doses at or above 9 x 10(5) units (400 micrograms)m-2 were associated with hypotension, abnormal liver enzymes, leucopenia and mild renal impairment in a substantial proportion of patients. RhTNF was cleared from plasma with a half life of approximately 20 minutes but non-linear pharmacokinetics lymphoma, improvements in their tumours were recorded. RhTNF was noted to produce rapid increases in serum C-reactive protein concentrations. Endogenous TNF levels were not found to be elevated in 72 cancer patients. TNF deserves further therapeutic evaluation and these observations support its biological importance as an endogenous pyrogen, mediator of acute phase protein responses, and a mediator of endotoxic shock.
Author(s): Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell DR, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 1987
Volume: 56
Issue: 6
Pages: 803-808
Print publication date: 01/12/1987
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
PubMed id: 3435706
